Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 PS Ratio is 8.32 as of Aug. 09, 2026, which is 74% above its 10-year median of 4.78. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 953 Drug Manufacturers companies, Sai Parenteral's ranks worse than 84.16% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sai Parenteral's's share price is ₹569.70.
Sai Parenteral's's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was ₹68.47. Hence, Sai Parenteral's's PS Ratio for today is 8.32.
Warning Sign:
Sai Parenteral's Ltd stock PS Ratio (=5.09) is close to 1-year high of 5.52.
The historical rank and industry rank for Sai Parenteral's's PS Ratio or its related term are showing as below:
NSE:SAIPARENT'
s PS Ratio Range Over the Past 10 Years
Min: 3.62 Med: 4.78 Max: 8.32
Current: 8.32
During the past 3 years, Sai Parenteral's's highest PS Ratio was 8.32. The lowest was 3.62. And the median was 4.78.
NSE:SAIPARENT's PS Ratio is ranked worse than 84.16% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs NSE:SAIPARENT: 8.32
Sai Parenteral's (NSE:SAIPARENT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Sai Parenteral's PS Ratio Related Terms
Sai Parenteral's PS Ratio Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's PS Ratio Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
PS Ratio
0.00
0.00
0.00
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
PS Ratio
0.00
0.00
0.00
0.00
NSE:SAIPARENT vs LLY, JNJ, ABBV: PS Ratio Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sai Parenteral's's Share Price of today is ₹569.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sai Parenteral's's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was ₹68.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sai Parenteral's (NSE:SAIPARENT) has a PS Ratio of 8.32 as of Aug. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sai Parenteral's and its competitors. This is 74% above median its historical median of 4.78. Over the past decade, Sai Parenteral's' PS Ratio has ranged from 3.62 to 8.32. According to the industry distribution chart, Sai Parenteral's ranks #802 out of 953 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Sai Parenteral's' PS Ratio too high?
Sai Parenteral's' current PS Ratio of 8.32 is 74% above median its 10-year median of 4.78. Over the past 10 years, this metric has ranged from a low of 3.62 to a high of 8.32. The Drug Manufacturers industry median PS Ratio is 2.35. Sai Parenteral's' value of 8.32 is 254% above this industry median. Based on the distribution chart, Sai Parenteral's ranks #802 out of 953 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #802 out of 953 companies for PS Ratio. This places Sai Parenteral's in the lower half of its industry. The industry median PS Ratio is 2.35. Sai Parenteral's' value of 8.32 is 254% above this benchmark. Historically, Sai Parenteral's' own PS Ratio has ranged from 3.62 to 8.32 over the past decade. While the company's 10-year median is 4.78 vs. the industry median of 2.35, Sai Parenteral's has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current PS Ratio of 8.32 is 254% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current PS Ratio is 8.32, which is 74% above median its own 10-year median of 4.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current PS Ratio of 8.32. The current PS Ratio is 8.32, which is 74% above median its 10-year median of 4.78 and 254% above the Drug Manufacturers industry median of 2.35. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current PS Ratio is 8.32 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
